Almonertinib Clinical Trials
6 recruitingDrug
Phase 34Phase 22Phase 11
Showing 1–6 of 6 trials
Recruiting
Phase 2
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Sichuan University40 enrolled1 locationNCT06951464
Recruiting
Phase 1Phase 2
A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
Sun Yat-sen University71 enrolled1 locationNCT06947811
Recruiting
Phase 3
MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.
Lung Cancer
Guangdong Association of Clinical Trials192 enrolled1 locationNCT04841811
Recruiting
Phase 3
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Metastatic
Shanghai Cancer Hospital, China300 enrolled1 locationNCT05800223
Recruiting
Phase 3
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases
Brain MetastasesRadiotherapyEGFR Activating Mutation
Sun Yat-sen University232 enrolled1 locationNCT05768490
Recruiting
Phase 3
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.150 enrolled1 locationNCT04951635